EUVIMEDEUVIMED entdecken
Multizentrische Studie

METTL14 is decreased and regulates m 6 A modification of α‐synuclein in Parkinson's disease

Honghu He, Qinxin Zhang, Jiajia Liao, Jiang Lei, Man Luo, Jianyi Huang, Meiling Chen, Yuefei Shen, Jin Wang, Pingyi Xu, Yousheng Xiao iD

Journal of Neurochemistry · 2023-08 · 166 (3) · 609-622

DOI: 10.1111/jnc.15882 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neurochemistry, online erschienen am 13.06.2023. Verfasst von Honghu He und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6‐methyladenosine (m6A), an emerging modification of messenger RNA, has been implicated in many biological processes. However, its role in Parkinson's disease (PD) remains largely unknown. Here, we investigated the role of m6A modification and its underlying mechanism in PD. First, 86 individuals with PD and 86 healthy controls were recruited from a pilot multicenter cohort. Levels of m6A and its modulators in peripheral blood mononuclear cells of patients with PD and controls were measured using an m6A RNA methylation quantification kit and quantitative real‐time PCR. The underlying mechanism of m6A modification in PD was investigated in vitro through RNA immunoprecipitation assay, RNA stability assay, gene silencing or overexpression, western blot, and confocal immunoassay. The results show that mRNA levels of m6A, METTL3, METTL14 , and YTHDF2 in patients with PD were significantly lower than in healthy controls, and METTL14 was the main factor involved in abnormal m6A modification. Area under the curve (AUC) analysis suggests METTL14 may provide excellent diagnostic capability for PD, especially when combined with plasma α‐synuclein (α‐syn). Spearman correlation analysis identified that METTL14 was moderately negatively correlated with plasma α‐syn and the motor function of PD. Mechanistic experiments demonstrated that Mettl14 targets and regulates the expression of the α‐syn gene using its methylation function. Overexpression of Mettl14 dramatically increased m 6 A modification of α‐syn mRNA and weakened its stability. Further results suggest that α‐syn mRNA was modified by Mettl14 binding of an m 6 A motif in the coding region of α‐syn mRNA, while the reading protein Ythdf2 was involved in recognizing m 6 A‐modified α‐syn mRNA. Taken together, our results reveal the potential of METTL14 as a novel diagnostic biomarker for PD and identify modification of pathogenic α‐syn protein by METTL14 via an m 6 A‐YTHDF2‐dependent mechanism. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinParkinson DiseaseHumansLeukocytes, MononuclearMethyltransferasesRNATranscription Factors

Stichwörter der Autor:innen

METTL14Parkinson's diseasebiomarkerm6A modificationα-Synuclein

Substanzen

alpha-SynucleinMethyltransferasesMETTL14 protein, humanMETTL3 protein, humanRNATranscription FactorsSNCA protein, human

Autor:innen und Institutionen

  • Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Rehabilitation Medicine, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
  • Department of Neurology, People's Hospital of Chongzuo city, Chongzuo, China.
  • Department of Neurology, Affiliated Hospital of Guilin Medical College, Guilin, China.
  • Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Yousheng Xiao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, H., Zhang, Q., Liao, J., Lei, J., Luo, M., Huang, J., Chen, M., Shen, Y., Wang, J., Xu, P., & Xiao, Y. (2023). METTL14 is decreased and regulates m 6 A modification of α‐synuclein in Parkinson's disease. Journal of Neurochemistry, 166(3), 609-622. https://doi.org/10.1111/jnc.15882

Vancouver

He H, Zhang Q, Liao J, Lei J, Luo M, Huang J, et al. METTL14 is decreased and regulates m 6 A modification of α‐synuclein in Parkinson's disease. Journal of Neurochemistry. 2023;166(3):609-622. doi:10.1111/jnc.15882

BibTeX
@article{He2023,
  author = {He, Honghu and Zhang, Qinxin and Liao, Jiajia and Lei, Jiang and Luo, Man and Huang, Jianyi and Chen, Meiling and Shen, Yuefei and Wang, Jin and Xu, Pingyi and Xiao, Yousheng},
  title = {METTL14 is decreased and regulates m 6 A modification of α‐synuclein in Parkinson's disease},
  journal = {Journal of Neurochemistry},
  year = {2023},
  volume = {166},
  number = {3},
  pages = {609--622},
  doi = {10.1111/jnc.15882}
}
Kostenlos starten →